BridgeBio Pharma Inc (BBIO)
28.01
-0.84
(-2.91%)
USD |
NASDAQ |
May 31, 16:00
28.01
0.00 (0.00%)
After-Hours: 20:00
BridgeBio Pharma Gross Profit (TTM): 216.20M for March 31, 2024
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 216.20M |
| December 31, 2023 | 6.857M |
| September 30, 2023 | 6.933M |
| June 30, 2023 | 3.039M |
| March 31, 2023 | 75.04M |
| December 31, 2022 | 74.21M |
| September 30, 2022 | 84.33M |
| Date | Value |
|---|---|
| June 30, 2022 | 85.62M |
| March 31, 2022 | 66.49M |
| December 31, 2021 | 66.60M |
| September 30, 2021 | 55.39M |
| June 30, 2021 | 62.63M |
| March 31, 2021 | 8.711M |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (TTM) Range, Past 5 Years
3.039M
Minimum
Jun 2023
216.20M
Maximum
Mar 2024
62.47M
Average
66.49M
Median
Mar 2022
Gross Profit (TTM) Benchmarks
| Pfizer Inc | 31.64B |
| Alnylam Pharmaceuticals Inc | 1.682B |
| Regenxbio Inc | 49.34M |
| Arvinas Inc | -- |
| IDEAYA Biosciences Inc | -- |